利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

155 条记录 (耗时 0.021 秒)

    METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASE
    82.
    发明公开
    METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASE 审中-公开
    方法和组合物疾病治疗

    公开(公告)号：EP1965803A1

    公开(公告)日：2008-09-10

    申请号：EP06839043.4

    申请日：2006-12-05

    申请人： Biomarin Pharmaceutical Inc.

    发明人： OPPENHEIMER, Daniel, I. ,  KAKKIS, Emil, D. ,  DORENBAUM, Alejandro

    IPC分类号： A61K31/519 ,  A61P9/10 ,  A61P9/12

    CPC分类号： A61K31/519 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention is directed to a novel methods and compositions for the therapeutic intervention of vascular complications associated with diabetes, hyperlipidemias, and various cardiovascular disorders including but not limited to recalcitrant hypertension, coronary artery disease, pulmonary arterial hypertension, congestive heart failure, and hemolytic anemias. More specifically, the specification describes methods and compositions for treating such vascular disorders using compositions comprising BH4 and derivative thereof. Combination therapies of BH4 and other therapeutic regimens are contemplated.

    ROOM TEMPERATURE STABLE AQUEOUS LIQUID PHARMACEUTICAL COMPOSITION
    83.
    发明公开
    ROOM TEMPERATURE STABLE AQUEOUS LIQUID PHARMACEUTICAL COMPOSITION 审中-公开
    在室温下稳定的水性药物液体组成

    公开(公告)号：EP1850854A1

    公开(公告)日：2007-11-07

    申请号：EP05724171.3

    申请日：2005-02-25

    申请人： Biomarin Pharmaceutical Inc.

    发明人： MEDICIS PEDIATRICS, INC. ,  CLEMENTE, Emmett ,  PATEL, Bhiku ,  BHATIA, Kuljit ,  SORGI, Frank, L. ,  KAKKIS, Emil, D.

    IPC分类号： A61K31/545

    CPC分类号： A61K9/0095 ,  A61K47/26

    摘要： A liquid pharmaceutical composition is contemplated that comprises a pharmaceutically effective amount of a drug dissolved or dispersed in an aqueous medium. The aqueous medium consists essentially of water, about 3% to about 10% w/v polyvinylpyrrolidone, about 60% to about 75% w/v of C3-C6 polyol that includes more than 55% w/v of a non-reducing disaccharide, trisaccharide or tetrasaccharide such as sucrose, optionally about 0.0 1% to about 0.5% w/v of a glycyrrhetic acid, glycyrrhizinate derivative or salt thereof, and one or more flavorants, and preferably includes one or more preservatives. The liquid composition is room temperature stable, and may have a pleasant taste.

    Attenuation of fibroblast proliferation
    85.
    发明公开
    Attenuation of fibroblast proliferation 审中-公开
    减少成纤维细胞增殖

    公开(公告)号：EP1839671A2

    公开(公告)日：2007-10-03

    申请号：EP06077220.9

    申请日：2000-11-28

    申请人： BioMarin Pharmaceutical Inc.

    发明人： Denholm, Elizabeth M. ,  Silver, Paul J. ,  Cauchon, Elizabeth

    IPC分类号： A61K38/46

    CPC分类号： A61K38/51 ,  C12Y402/02019

    摘要： Highly purified and specific glycosaminoglycan degrading enzymes, chondroitinase B and chondroitinase AC, are used to treat fibroproliferative diseases. The enzymatic removal of chondroitin sulfate B (dermatan sulfate), and to a lesser extent, chondroitin sulfate A or C, from cell surfaces effectively decreases growth factor receptors on the cells and thereby decreases the cell proliferative response to such growth factors. In addition, removal of chondroitin sulfates reduces secretion of collagen, one of the major extracellular matrix components. Through the combined inhibition of fibroblast proliferation and collagen synthesis, treatment with chondroitinase B or chondroitinase AC decreases the size of fibrous tissue found in psoriasis, seleroderma, keloids, pulmonary fibrosis and surgical adhesions.

    摘要翻译： 高纯度和特异性糖胺聚糖降解酶，软骨素酶B和软骨素酶AC用于治疗纤维增殖性疾病。 从细胞表面酶促去除硫酸软骨素B（硫酸皮肤素）和较小程度的硫酸软骨素A或C有效地降低细胞上的生长因子受体，从而降低对这些生长因子的细胞增殖反应。 此外，硫酸软骨素的去除减少了胶原的分泌，胶原是主要的细胞外基质组分之一。 通过组合抑制成纤维细胞增殖和胶原合成，用软骨素酶B或软骨素酶AC处理降低了在银屑病，皮脂腺瘤，瘢痕瘤，肺纤维化和手术粘连中发现的纤维组织的大小。